/Investor DB

Digitalis Ventures — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Bonum Therapeuticsbonumtx.comin𝕏Series A · Nov 2022 · $93M

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.

BiotechHealthtechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in

BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in

Co-investorsRiverVest Venture PartnersRoche Venture FundVivo Capital3x5 PartnersCodon Capital

Matchpoint TherapeuticsinOct 2022

Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.

BiotechCambridge, US

Andre Turenne(Executive Officer, Director)in

BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)

Co-investorsAccess BiotechnologySanofi VenturesAccess IndustriesAlexandriaAtlas Venture

MySimplePetLabinSeries A · Oct 2022 · $5M

Centennial, US

Dennis J. Chmiel(Executive Officer, Director)inJen Hagness(Executive Officer, Director)inNancy A. Willerton(Executive Officer, Director)Dennis J. Chmiel Jr.(Executive Officer, Director)

BoardCindy Cole(Director)Jeremy L. Friese(Director)

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Napo Pet Insurance

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.